Phosphatidylinositol 3-kinase and Mek1/2 are necessary for insulin-like growth factor-i-induced vascular endothelial growth factor synthesis in prostate epithelial cells: A role for hypoxia-inducible factor-1?

Molecular Cancer Research

Volumn 1, Issue 4, 2003, Pages 312-322

  Burroughs, Kevin D ^a   Oh, Jennifer ^a   Barrett, J Carl ^b   DiAugustine, Richard P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FOS; SOMATOMEDIN C; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIA RESPONSE ELEMENT; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; REPORTER GENE; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; NUCLEAR PROTEINS; PROSTATE; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

VECTORS;

EID: 0037293542     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (Lond.), 1: 27-31, 1995.
2. Melnyk, O., Zimmerman, M., Kim, K. J., and Shuman, M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol., 161: 960-963, 1999.
3. Heimann, R., Ferguson, D., Gray, S., and Hellman, S. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res. Treat., 52: 147-158, 1998.
4. Brawer, M. K. Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer, 78: 345-349, 1996.
5. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D., and Bigler, S. A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, 73: 678-687, 1994.
6. Engels, K., Fox, S. B., Whitehouse, R. M., Gatter, K. C., and Harris, A. L. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J. Pathol., 181: 207-212, 1997.
7. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.
8. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., and Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 5: 1806-1814, 1991.
9. Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E., and Neufeld, G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem., 272: 7151-7158, 1997.
10. Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., and Kreutzer, D. L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol., 157: 2329-2333, 1997.
11. Harper, M. E., Glynne-Jones, E., Goddard, L., Thurston, V. J., and Griffiths, K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br. J. Cancer, 74: 910-916, 1996.
12. Mazzucchelli, R., Montironi, R., Santinelli, A., Lucarini, G., Pugnaloni, A., and Biagini, G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgenablated patients. Prostate, 45: 72-79, 2000.
13. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
14. Wang, G. L. and Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem., 270: 1230-1237, 1995.
15. Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA, 92: 5510-5514, 1995.
16. Salceda, S. and Caro, J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-iuduced changes. J. Biol. Chem., 272: 22642-22647, 1997.
17. Jiang, B. H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem., 271: 17771-17778, 1996.
18. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J., 17: 5085-5094, 1998.
19. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor la expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
20. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth & Differ., 12: 363-369, 2001.
21. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.
22. Gille, J., Swerlick, R. A., and Caughman, S. W. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/ VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.
23. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D., and Siemeister, G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene, 15: 669-676, 1997.
24. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H. A., Kohno, K., and Kuwano, M. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. Possible roles of SP-1. J. Biol. Chem., 271: 28220-28228, 1996.
25. Tanaka, T., Kanai, H., Sekiguchi, K., Aihara, Y., Yokoyama, T., Arai, M., Kanda, T., Nagai, R., and Kurabayashi, M. Induction of VEGF gene transcription by IL-1β is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J. Mol. Cell. Cardiol., 32: 1955-1967, 2000.
26. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55: 4575-4580, 1995.
27. Goad, D. L., Rubin, J., Wang, H., Tashjian, A. H., Jr., and Patterson, C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology, 137: 2262-2268, 1996.
28. Akagi, Y., Liu, W., Zebrowski, B., Xie, K., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res., 58: 4008-4014, 1998.
29. Punglia, R. S., Lu, M., Hsu, J., Kuroki, M., Tolentino, M. J., Keough, K., Levy, A. P., Levy, N. S., Goldberg, M. A., D'Amato, R. J., and Adamis, A. P. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes, 46: 1619-1626, 1997.
30. Bermont, L., Lamielle, F., Fauconnet, S., Esumi, H., Weisz, A., and Adessi, G. L. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int. J. Cancer, 85: 117-123, 2000.
31. Blakesley, V. A., Scrimgeour, A., Esposito, D., and Le Roith, D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev., 7: 153-159, 1996.
32. Milanini, J., Vinals, F., Pouyssegur, J., and Pages, G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem., 273: 18165-18172, 1998.
33. Jung, Y. D., Nakano, K., Liu, W., Gallick, G. E., and Ellis, L. M. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res., 59: 4804-4807, 1999.
34. Ruan, W., Powell-Braxton, L., Kopchick, J. J., and Kleinberg, D. L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology, 140: 1984-1989, 1999.
35. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington, DC), 279: 563-566, 1998.
36. Stattin, P., Bylund, A., Rinaldi, S., Biessy, C., Dechaud, H., Stenman, U. H., Egevad, L., Riboli, E., Hallmans, G., and Kaaks, R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst., 92: 1910-1917, 2000.
37. Seger, R. and Krebs, E. G. The MAPK signaling cascade. FASEB J., 9: 726-735, 1995.
38. Damert, A., Ikeda, E., and Risau, W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-I-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J., 327: 419-423, 1997.
39. Kimura, H., Weisz, A., Kurashima, Y., Hashimoto, K., Ogura, T., D'Acquisto, F., Addco, R., Makuuchi, M., and Esumi, H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-I activity by nitric oxide. Blood, 95: 189-197, 2000.
40. Janknecht, R., Cahill, M. A., and Nordheim, A. Signal integration at the c-fos promoter. Carcinogenesis (Lond.), 16: 443-450, 1995.
41. Olive, M., Krylov, D., Echlin, D. R., Gardner, K., Taparowsky, E., and Vinson, C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem., 272: 18586-18594, 1997.
42. Semenza, G. L. and Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 12: 5447-5454, 1992.
43. Smith, L. E., Shen, W., Perruzzi, C., Soker, S., Kinose, F., Xu, X., Robinson, G., Driver, S., Bischoff, J., Zhang, B., Schaeffer, J. M., and Senger, D. R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med., 5: 1390-1395, 1999.
44. Hellstrom, A., Perruzzi, C., Ju, M., Engstrom, E., Hard, A. L., Liu, J. L., Albertsson-Wikland, K., Carlsson, B., Niklasson, A., Sjodell, L., LeRoith, D., Senger, D. R., and Smith, L. E. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. USA, 98: 5804-5808, 2001.
45. Jones, J. I. and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
46. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396, 1998.
47. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., and Stampfer, M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst., 91: 620-625, 1999.
48. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst., 91: 151-156, 1999.
49. Khandwala, H. M., McCutcheon, I. F., Flyvbjerg, A., and Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 21: 215-244, 2000.
50. Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 49: 407-424, 1998.
51. Reiss, K., D'Ambrosio, C., Tu, X., Tu, C., and Baserga, R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin. Cancer Res., 4: 2647-2655, 1998.
52. Dunn, S. E., Ehrlich, M., Sharp, N. J., Reiss, K., Solomon, G., Hawkins, R., Baserga, R., and Barrett, J. C. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.
53. Burfeind, P., Chemicky, C. L., Rininsland, F., and Ilan, J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA, 93: 7263-7268, 1996.
54. Long, L., Rubin, R., Baserga, R., and Brodt, P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 55: 1006-1009, 1995.
55. Chemicky, C. L., Yi, L., Tan, H., Gan, S. U., and Ilan, J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther., 7: 384-395, 2000.
56. Quevedo, C., Alcazar, A., and Salinas, M. Two different signal transduction pathways are implicated in the regulation of initiation factor 2B activity in insulin-like growth factor-1-stimulated neuronal cells. J. Biol. Chem., 275: 19192-19197, 2000.
57. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin, I. E., and Liotta, L. A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 20: 1981-1989, 2001.
58. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H. F., Jr., and Weber, M. J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res., 59: 279-284, 1999.
59. Price, D. T., Rocca, G. D., Guo, C., Ballo, M. S., Schwinn, D. A., and Luttrell, L. M. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol., 162: 1537-1542, 1999.
60. Park, J. S., Qiao, L., Su, Z. Z., Hinman, D., Willoughby, K., McKinstry, R., Yacoub, A., Duigou, G. J., Young, C. S., Grant, S., Hagan, M. P., Ellis, E., Fisher, P. B., and Dent, P. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene, 20: 3266-3280, 2001.
61. Hossain, M. A., Bouton, C. M., Pevsner, J., and Laterra, J. Induction of vascular endothelial growth factor in human astrocytes by lead. Involvement of a protein kinase C/activator protein-1 complex-dependent and hypoxia-inducible factor 1-independent signaling pathway. J. Biol. Chem., 275: 27874-27882, 2000.
62. Hu, Y. L., Tee, M. K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., and Jaffe, R. B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst., 93: 762-768, 2001.
63. Saez, E., Rutberg, S. E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S. H., and Spiegelman, B. M. c-fos is required for malignant progression of skin tumors. Cell, 82: 721-732, 1995.
64. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
65. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L., and Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem., 277: 27975-27981, 2002.
66. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem., 277: 38205-38211, 2002.
67. Maity, A., Pore, N., Lee, J., Solomon, D., and O'Rourke, D. M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res., 60: 5879-5886, 2000.
68. Alfranca, A., Gutierrez, M. D., Vara, A., Aragones, J., Vidal, F., and Landazuri, M. O. c-Jun and hypoxia-inducible factor I functionally cooperate in hypoxia-induced gene transcription. Mol. Cell. Biol., 22: 12-22, 2002.
69. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1 α in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999.
70. Weijerman, P. C., Konig, J. J., Wong, S. T., Niesters, H. G., and Peehl, D. M. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res., 54: 5579-5583, 1994.